These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
456 related articles for article (PubMed ID: 25029118)
1. Associations between mutations and histologic patterns of mucin in lung adenocarcinoma: invasive mucinous pattern and extracellular mucin are associated with KRAS mutation. Kadota K; Yeh YC; D'Angelo SP; Moreira AL; Kuk D; Sima CS; Riely GJ; Arcila ME; Kris MG; Rusch VW; Adusumilli PS; Travis WD Am J Surg Pathol; 2014 Aug; 38(8):1118-27. PubMed ID: 25029118 [TBL] [Abstract][Full Text] [Related]
2. The clinicopathological significance of ALK rearrangements and KRAS and EGFR mutations in primary pulmonary mucinous adenocarcinoma. Qu Y; Che N; Zhao D; Zhang C; Su D; Zhou L; Zhang L; Wang C; Zhang H; Wei L Tumour Biol; 2015 Aug; 36(8):6417-24. PubMed ID: 25813151 [TBL] [Abstract][Full Text] [Related]
3. [Relevance of molecular alterations in histopathologic subtyping of lung adenocarcinoma based on 2011 International Multidisciplinary Lung Adenocarcinoma Classification]. Liu B; Shi SS; Wang X; Xu Y; Zhang XH; Yu B; Lu ZF; Wang JD; Zhou XJ Zhonghua Bing Li Xue Za Zhi; 2012 Aug; 41(8):505-10. PubMed ID: 23157740 [TBL] [Abstract][Full Text] [Related]
4. Validation of the IASLC/ATS/ERS lung adenocarcinoma classification for prognosis and association with EGFR and KRAS gene mutations: analysis of 440 Japanese patients. Yoshizawa A; Sumiyoshi S; Sonobe M; Kobayashi M; Fujimoto M; Kawakami F; Tsuruyama T; Travis WD; Date H; Haga H J Thorac Oncol; 2013 Jan; 8(1):52-61. PubMed ID: 23242438 [TBL] [Abstract][Full Text] [Related]
5. MUC5AC enhances tumor heterogeneity in lung adenocarcinoma with mucin production and is associated with poor prognosis. Dong Y; Zhou L; Zhao D; Li K; Liu Z; Che N; Liu H Jpn J Clin Oncol; 2020 Jun; 50(6):701-711. PubMed ID: 32083303 [TBL] [Abstract][Full Text] [Related]
6. KRAS mutations are associated with solid growth pattern and tumor-infiltrating leukocytes in lung adenocarcinoma. Rekhtman N; Ang DC; Riely GJ; Ladanyi M; Moreira AL Mod Pathol; 2013 Oct; 26(10):1307-19. PubMed ID: 23619604 [TBL] [Abstract][Full Text] [Related]
7. EGFR L858R mutation is associated with lung adenocarcinoma patients with dominant ground-glass opacity. Yang Y; Yang Y; Zhou X; Song X; Liu M; He W; Wang H; Wu C; Fei K; Jiang G Lung Cancer; 2015 Mar; 87(3):272-7. PubMed ID: 25582278 [TBL] [Abstract][Full Text] [Related]
8. Clinicopathological features of lung adenocarcinoma with KRAS mutations. Kakegawa S; Shimizu K; Sugano M; Miyamae Y; Kaira K; Araki T; Nakano T; Kamiyoshihara M; Kawashima O; Takeyoshi I Cancer; 2011 Sep; 117(18):4257-66. PubMed ID: 21387273 [TBL] [Abstract][Full Text] [Related]
9. Associations between the IASLC/ATS/ERS lung adenocarcinoma classification and EGFR and KRAS mutations. Clay TD; Russell PA; Do H; Sundararajan V; Conron M; Wright GM; Dobrovic A; Moore MM; McLachlan SA Pathology; 2016 Jan; 48(1):17-24. PubMed ID: 27020204 [TBL] [Abstract][Full Text] [Related]
10. KRAS Mutation Is a Significant Prognostic Factor in Early-stage Lung Adenocarcinoma. Kadota K; Sima CS; Arcila ME; Hedvat C; Kris MG; Jones DR; Adusumilli PS; Travis WD Am J Surg Pathol; 2016 Dec; 40(12):1579-1590. PubMed ID: 27740967 [TBL] [Abstract][Full Text] [Related]
11. Mucinous lung adenocarcinoma, particularly referring to EGFR-mutated mucinous adenocarcinoma. Wakejima R; Inamura K; Ninomiya H; Nagano H; Mun M; Okumura S; Okubo K; Ishikawa Y Pathol Int; 2020 Feb; 70(2):72-83. PubMed ID: 31859434 [TBL] [Abstract][Full Text] [Related]
12. KRAS and NKX2-1 Mutations in Invasive Mucinous Adenocarcinoma of the Lung. Hwang DH; Sholl LM; Rojas-Rudilla V; Hall DL; Shivdasani P; Garcia EP; MacConaill LE; Vivero M; Hornick JL; Kuo FC; Lindeman NI; Dong F J Thorac Oncol; 2016 Apr; 11(4):496-503. PubMed ID: 26829311 [TBL] [Abstract][Full Text] [Related]
13. Mutational Profile and New IASLC/ATS/ERS Classification Provide Additional Prognostic Information about Lung Adenocarcinoma: A Study of 125 Patients from Brazil. de Melo AC; Karen de Sá V; Sternberg C; Olivieri ER; Werneck da Cunha I; Fabro AT; Carraro DM; de Barros e Silva MJ; Pimenta Inada HK; de Mello ES; Soares FA; Takagaki T; Ferreira CG; Capelozzi VL Oncology; 2015; 89(3):175-86. PubMed ID: 25833149 [TBL] [Abstract][Full Text] [Related]
14. Cytomorphologic features of advanced lung adenocarcinomas tested for EGFR and KRAS mutations: a retrospective review of 50 cases. Marotti JD; Schwab MC; McNulty NJ; Rigas JR; DeLong PA; Memoli VA; Tsongalis GJ; Padmanabhan V Diagn Cytopathol; 2013 Jan; 41(1):15-21. PubMed ID: 21681971 [TBL] [Abstract][Full Text] [Related]
15. HNF4α as a marker for invasive mucinous adenocarcinoma of the lung. Sugano M; Nagasaka T; Sasaki E; Murakami Y; Hosoda W; Hida T; Mitsudomi T; Yatabe Y Am J Surg Pathol; 2013 Feb; 37(2):211-8. PubMed ID: 23108025 [TBL] [Abstract][Full Text] [Related]
16. Retrospective Multicenter Study Investigating the Role of Targeted Next-Generation Sequencing of Selected Cancer Genes in Mucinous Adenocarcinoma of the Lung. Righi L; Vatrano S; Di Nicolantonio F; Massa F; Rossi G; Cavazza A; Volante M; Votta A; Izzo S; Lo Iacono M; Ardissone F; Di Maio M; Novello S; Scagliotti GV; Papotti M J Thorac Oncol; 2016 Apr; 11(4):504-15. PubMed ID: 26774193 [TBL] [Abstract][Full Text] [Related]
17. Frequency of driver mutations in lung adenocarcinoma from female never-smokers varies with histologic subtypes and age at diagnosis. Zhang Y; Sun Y; Pan Y; Li C; Shen L; Li Y; Luo X; Ye T; Wang R; Hu H; Li H; Wang L; Pao W; Chen H Clin Cancer Res; 2012 Apr; 18(7):1947-53. PubMed ID: 22317764 [TBL] [Abstract][Full Text] [Related]
18. Unique Genetic and Survival Characteristics of Invasive Mucinous Adenocarcinoma of the Lung. Shim HS; Kenudson M; Zheng Z; Liebers M; Cha YJ; Hoang Ho Q; Onozato M; Phi Le L; Heist RS; Iafrate AJ J Thorac Oncol; 2015 Aug; 10(8):1156-62. PubMed ID: 26200269 [TBL] [Abstract][Full Text] [Related]
19. Clinicopathologic characteristics of ALK rearrangements in primary lung adenocarcinoma with identified EGFR and KRAS status. Wang J; Dong Y; Cai Y; Zhou L; Wu S; Liu G; Su D; Li X; Qin N; Nong J; Jia H; Zhang Q; Mu J; Zeng X; Zhang H; Zhang S; Zhang Z J Cancer Res Clin Oncol; 2014 Mar; 140(3):453-60. PubMed ID: 24442099 [TBL] [Abstract][Full Text] [Related]
20. Lepidic predominant adenocarcinoma and invasive mucinous adenocarcinoma of the lung exhibit specific mucin expression in relation with oncogenic drivers. Duruisseaux M; Antoine M; Rabbe N; Rodenas A; Mc Leer-Florin A; Lacave R; Poulot V; Duchêne B; Van Seuningen I; Cadranel J; Wislez M Lung Cancer; 2017 Jul; 109():92-100. PubMed ID: 28577958 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]